Video

Dr. Karlan Describes AMG 386 Side Effects

Author(s):

Beth Y. Karlan MD

Dr. Karlan Describes AMG 386 Side Effects Found in the Phase II Ovarian Cancer Trial

Beth Y. Karlan MD, a Director at Cedars-Sinai Women's Cancer Research Institute Describes AMG 386 Side Effects Found in the Phase II Ovarian Cancer Trial

Related Videos
Dingwei Ye, MD, PhD
Areej El-Jawahri, MD, associate director, Cancer Outcomes Research and Education Program, director, Bone Marrow Transplant Survivorship Program, associate professor, medicine, Massachusetts General Hospital
Sandy Srinivas, MD
David Rimm, MD, PhD
Angeles A. Secord, MD, MHSc
Alexandra Drakaki, MD, PhD
Idoroenyi Amanam, MD
Sagar Lonial, MD, FACP
Leo I. Gordon, MD
Andrea Wolf, MD, MPH
Related Content
Gursel Aktan, MD, PhD
September 20th 2024

Pembrolizumab-Based Regimens Earn Positive CHMP Opinion in Endometrial and Cervical Cancers

Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD
January 11th 2024

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

Anna Dańska-Bidzińska, MD, a gynecologist from Warsaw Medical University in Warsaw, Poland
September 18th 2024

Lenvatinib Plus Pembrolizumab Affords Deep and Durable Responses in Endometrial Cancer

R. Wendel Naumann, MD
October 26th 2023

Naumann Discusses Notable Research Efforts in Endometrial Cancer

FDA
September 16th 2024

FDA Lifts Partial Clinical Hold on Trials Evaluating Azenosertib in Advanced Solid Tumors

Gottfried E. Konecny, MD
September 15th 2024

TORL-1-23 Is Tolerable, Active in Heavily Pretreated CLDN6+ Advanced Ovarian Cancer, Other Solid Tumors